Rapport Therapeutics, Inc. RAPP
We take great care to ensure that the data presented and summarized in this overview for Rapport Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in RAPP
Top Purchases
Top Sells
About RAPP
Insider Transactions at RAPP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Krishnaswamy Yeleswaram Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,840
-0.95%
|
$85,200
$30.05 P/Share
|
|
Dec 31
2025
|
Krishnaswamy Yeleswaram Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+2.91%
|
-
|
|
Dec 31
2025
|
David Bredt Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,567
-1.6%
|
$197,010
$30.05 P/Share
|
|
Dec 31
2025
|
David Bredt Chief Scientific Officer |
SELL
Grant, award, or other acquisition
|
Direct |
18,000
-4.2%
|
-
|
|
Dec 17
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
5,083
-4.92%
|
$147,407
$29.97 P/Share
|
|
Dec 17
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,833
-0.34%
|
$169,157
$29.97 P/Share
|
|
Dec 15
2025
|
David Bredt Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,500
-1.06%
|
$255,000
$30.32 P/Share
|
|
Nov 26
2025
|
Cheryl Gault Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.83%
|
$150,000
$30.1 P/Share
|
|
Nov 26
2025
|
Cheryl Gault Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.75%
|
$5,000
$1.8 P/Share
|
|
Nov 17
2025
|
David Bredt Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,500
-1.04%
|
$212,500
$25.12 P/Share
|
|
Nov 17
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
5,083
-6.39%
|
$127,075
$25.18 P/Share
|
|
Nov 17
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,833
-0.5%
|
$145,825
$25.18 P/Share
|
|
Oct 15
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
5,083
-5.59%
|
$127,075
$25.96 P/Share
|
|
Oct 15
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,833
-0.5%
|
$145,825
$25.93 P/Share
|
|
Oct 15
2025
|
David Bredt Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,500
-1.02%
|
$212,500
$25.95 P/Share
|
|
Sep 17
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
35,585
-22.09%
|
$925,210
$26.67 P/Share
|
|
Sep 17
2025
|
Abraham Ceesay Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,835
-3.27%
|
$1,061,710
$26.59 P/Share
|
|
Sep 15
2025
|
David Bredt Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,500
-1.0%
|
$204,000
$24.27 P/Share
|
|
Sep 12
2025
|
Steven M Paul |
BUY
Open market or private purchase
|
Indirect |
41,666
+37.15%
|
$999,984
$24.74 P/Share
|
|
Sep 12
2025
|
Reid M Huber |
BUY
Open market or private purchase
|
Direct |
20,400
+50.0%
|
$489,600
$24.48 P/Share
|
Last 12 Months Summary
Buy / Acquisition
115K
Shares
From
7
Insiders
| Open market or private purchase | 81.6K shares |
|---|---|
| Grant, award, or other acquisition | 23K shares |
| Exercise of conversion of derivative security | 10K shares |
Sell / Disposition
232K
Shares
From
5
Insiders
| Open market or private sale | 214K shares |
|---|---|
| Grant, award, or other acquisition | 18K shares |